Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Stock Information for Celularity Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Celularity Inc.

Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Celularity Announces Publication of "Senescence, NK cells, and cancer: navigating the crossroads of aging and disease" in the April 4, 2025, Issue of Frontiers in Immunology
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft(TM) Wound Care Products
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.